Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications.
about
Melatonin secretion occurs at a constant rate in both young and older men and women.Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disordersEfficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.Radioprotective effect of melatonin on radiation-induced lung injury and lipid peroxidation in rats.The duodenal mucosal bicarbonate secretion.Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice.Pharmacological advantages of melatonin in immunosenescence by improving activity of T lymphocytes.Drugs for insomnia.Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential.Intranasal melatonin nanoniosomes: pharmacokinetic, pharmacodynamics and toxicity studies.Mechanisms of Melatonin in Alleviating Alzheimer's Disease.Melatonin protects against transient focal cerebral ischemia in both reproductively active and estrogen-deficient female rats: the impact of circulating estrogen on its hormetic dose-response.Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats.Melatonin-induced calcium signaling in clusters of human and rat duodenal enterocytes.Melatonin decreases duodenal epithelial paracellular permeability via a nicotinic receptor-dependent pathway in rats in vivo.Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine.Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3.Lack of neuroprotection with pharmacological pretreatment in a paradigm for anticipated spinal cord lesions.Chronic and acute melatonin effects in gerbil global forebrain ischemia: long-term neural and behavioral outcome.Hypothermic effects of hops are antagonized with the competitive melatonin receptor antagonist luzindole in mice.Melatonin Pharmacokinetics Following Oral Administration in Preterm Neonates.Melatonin pretreatment improves gastric mucosal blood flow and maintains intestinal barrier function during hemorrhagic shock in dogs.Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats.Melatonin Alleviates the Epilepsy-Associated Impairments in Hippocampal LTP and Spatial Learning Through Rescue of Surface GluR2 Expression at Hippocampal CA1 Synapses.Circadian variation of portal, arterial and venous blood levels of melatonin in pigs and its relationship to food intake and sleep.Melatonin prevents oxidative stress in ovariectomized rats treated with aluminium.Melatonin improves neuroplasticity by upregulating the growth-associated protein-43 (GAP-43) and NMDAR postsynaptic density-95 (PSD-95) proteins in cultured neurons exposed to glutamate excitotoxicity and in rats subjected to transient focal cerebraEffects of melatonin on the serum levels of pro-inflammatory cytokines and tissue injury after renal ischemia reperfusion in rats.New dosage form for pulsatile delivery of melatonin: Development and testing in animal and human subjects
P2860
Q31711815-F61C7A92-6C64-42F2-BA6A-87FAAC22F78AQ33854026-36BEC2A7-A400-4DA3-870C-BF632E21D584Q34579202-A3B4FDC8-98C9-45D9-9B62-FE4916D5474CQ35369354-BB7B6FE1-31FE-4003-A3FC-0F35150D2CC5Q36216614-4939A6FC-3338-4BBE-BE10-A882414D5027Q36433222-11F42454-0099-492E-B5F9-4AD10EFE4C27Q37097412-8C983D37-8374-410F-94DE-B9CD5192913DQ38017272-1B0A1C97-6570-4B18-B400-19FD3627CAC9Q38031910-E3B6724B-A151-4C9C-AC7D-2A032EF5DCACQ38771820-33583246-F898-4ACF-A18A-97C734A4DE16Q39178920-94743250-C3D3-4DEF-B794-187D50903E0AQ39611464-2C35A32D-3B1B-4C28-ADFB-353D15ED0A13Q42011994-4919FA49-544F-4A41-98FD-3E1F455B42EAQ42437023-EE207028-311A-42BD-BA7D-2FAB15B93FF6Q42513194-9C25D897-712F-4F8B-B0BD-2550662682BAQ43748635-7C79468E-5A81-4100-818F-162F93B4DAEEQ45175176-6AC451DD-D499-430D-AF7D-67CF7409DC84Q46497023-25B8F6D6-B58D-4214-A4D9-AD961BF3B1E7Q46742291-C8E110E0-7F58-453B-BE87-75286972E3AAQ47795328-08501573-541E-4E1F-8A09-4398DA334E8DQ47940557-095CD05E-C88A-4958-84E7-92923797EE2EQ48107961-C1C586E8-8CC3-4B15-9C33-86FB7B2EF9A7Q48248885-E2759D0D-8611-42CB-9986-764F37233A33Q48302540-BEF06180-1889-410F-BC41-34A81124D276Q48735398-E327DDE8-3EA3-4E39-8819-AB8A314132E2Q51468756-F0555882-DD87-4272-91F8-D8ACB8138FBCQ53653338-F24083EC-E3F8-4044-87D0-9409D34207C7Q53665622-1E24A044-E5FF-43EA-9566-3FC6CFA06376Q58257306-77846779-452A-4EE7-9D2D-27AAFC6C9228
P2860
Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Pharmacokinetics and oral bioa ...... els and clinical implications.
@en
type
label
Pharmacokinetics and oral bioa ...... els and clinical implications.
@en
prefLabel
Pharmacokinetics and oral bioa ...... els and clinical implications.
@en
P2093
P2860
P1476
Pharmacokinetics and oral bioa ...... els and clinical implications.
@en
P2093
McLaughlin LG
Schabdach D
Yeleswaram K
P2860
P356
10.1111/J.1600-079X.1997.TB00302.X
P577
1997-01-01T00:00:00Z